

Laine E Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4952733/publications.pdf>

Version: 2024-02-01

97
papers

5,501
citations

81434

41
h-index

97045

71
g-index

97
all docs

97
docs citations

97
times ranked

8677
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
2	Racial Disparities in Invasive Management for Patients With Acute Myocardial Infarction With Chronic Kidney Disease. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011171.	1.4	1
3	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	1.2	12
4	Asthma and the Risk of SARS-CoV-2 Infection Among Children and Adolescents. <i>Pediatrics</i> , 2022, 149, .	1.0	14
5	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€œHF. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	3
6	Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. <i>American Heart Journal</i> , 2021, 231, 1-5.	1.2	73
7	RE:â€œADDRESSING EXTREME PROPENSITY SCORES VIA THE OVERLAP WEIGHTSâ€œ. <i>American Journal of Epidemiology</i> , 2021, 190, 189-190.	1.6	2
8	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561.	1.0	5
9	Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas. <i>Journal of Women's Health</i> , 2021, 30, 355-366.	1.5	9
10	Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry. <i>Journal of General Internal Medicine</i> , 2021, 36, 1319-1326.	1.3	52
11	Propensity score weighting for causal subgroup analysis. <i>Statistics in Medicine</i> , 2021, 40, 4294-4309.	0.8	22
12	Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach. <i>Clinical Trials</i> , 2021, 18, 570-581.	0.7	4
13	The Importance of the Design of Observational Studies in Comparative Effectiveness Research: Lessons from the GARFIELD-AF and ORBIT-AF registries. <i>American Heart Journal</i> , 2021, 243, 110-121.	1.2	3
14	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
15	Using Propensity Score Methods to Create Target Populations in Observational Clinical Research. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 466.	3.8	110
16	Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 345.e1-345.e22.	0.7	35
17	Propensity score weighting under limited overlap and model misspecification. <i>Statistical Methods in Medical Research</i> , 2020, 29, 3721-3756.	0.7	49
18	Overlap Weighting. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2417.	3.8	285

#	ARTICLE	IF	CITATIONS
19	Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). <i>JAMA Cardiology</i> , 2020, 5, 988.	3.0	16
20	Comparative effectiveness of hysterectomy versus myomectomy on one-year health-related quality of life in women with uterine fibroids. <i>Fertility and Sterility</i> , 2020, 113, 618-626.	0.5	38
21	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
22	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2020, 226, 85-93.	1.2	13
23	Matching with time-dependent treatments: A review and look forward. <i>Statistics in Medicine</i> , 2020, 39, 2350-2370.	0.8	23
24	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFREF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480.	1.9	47
25	Addressing Extreme Propensity Scores via the Overlap Weights. <i>American Journal of Epidemiology</i> , 2019, 188, 250-257.	1.6	216
26	Application of net reclassification index to non-nested and point-based risk prediction models: a review. <i>European Heart Journal</i> , 2019, 40, 1880-1887.	1.0	39
27	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 1192.	4.5	70
28	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Nephilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , 2019, 124, 1900-1906.	0.7	19
29	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the Tj ETQq1 1 0.784314 rgBT/Overlap	0.7	10
30	Separating variability in healthcare practice patterns from random error. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1247-1260.	0.7	0
31	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1063-1074.	1.2	147
32	Health Status Variation Across Practices in Outpatients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004668.	0.9	15
33	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	22
34	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	3.0	77
35	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004054.	0.9	30
36	The Comparing Options for Management: Patient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 95.e1-95.e10.	0.7	48

#	ARTICLE	IF	CITATIONS
37	Tools for Evaluating and Improving Causal Inference. <i>JAMA Cardiology</i> , 2018, 3, 907.	3.0	4
38	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 435-439.	1.0	9
39	Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000523.	1.2	32
40	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	34
41	Hospital Variation in Functional Recovery After Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	28
42	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017, 185, 140-149.	1.2	54
43	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	1.2	5
44	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017, 189, 40-47.	1.2	53
45	Unexplained Variation for Hospitals' Use of Inpatient Rehabilitation and Skilled Nursing Facilities After an Acute Ischemic Stroke. <i>Stroke</i> , 2017, 48, 2836-2842.	1.0	37
46	Transcatheter Versus Surgical Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 70, 439-450.	1.2	82
47	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	29
48	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation</i> , 2017, 135, 38-47.	1.6	16
49	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. <i>Stroke</i> , 2016, 47, 836-842.	1.0	67
50	The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry's Get With the Guidelines (GWTG) Medicare-linked database. <i>American Heart Journal</i> , 2016, 178, 65-73.	1.2	54
51	Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 513-522.	0.9	42
52	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016, 134, 1122-1124.	1.6	6
53	Patient factors associated with quality of life in atrial fibrillation. <i>American Heart Journal</i> , 2016, 182, 135-143.	1.2	62
54	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. <i>Clinical Cardiology</i> , 2016, 39, 119-125.	0.7	6

#	ARTICLE	IF	CITATIONS
55	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 661.	3.8	33
56	Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR. <i>Clinical Cardiology</i> , 2016, 39, 585-595.	0.7	64
57	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 592-599.e1.	0.6	49
58	Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2016, 1, 147.	3.0	80
59	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. <i>American Heart Journal</i> , 2016, 174, 29-36.	1.2	82
60	Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 109-116.	0.9	9
61	Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. <i>JAMA Cardiology</i> , 2016, 1, 37.	3.0	56
62	Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 292-300.	0.9	10
63	Cumulative Incidence of Death and Rehospitalization Among the Elderly in the First Year after NSTEMI. <i>American Journal of Medicine</i> , 2015, 128, 582-590.	0.6	35
64	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. <i>JAMA Internal Medicine</i> , 2015, 175, 207.	2.6	72
65	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	68
66	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. <i>BMJ Open</i> , 2015, 5, e007901.	0.8	7
67	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 488-494.	1.6	224
68	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 393-402.	0.9	173
69	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2433.	3.8	50
70	Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2015, 169, 515-522.e1.	1.2	33
71	Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 567-575.	0.9	9
72	The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, ehv476.	1.0	316

#	ARTICLE	IF	CITATIONS
73	Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 576-585.	0.9	12
74	Antiarrhythmic Drug Use in Patients <65 Years With Atrial Fibrillation and Without Structural Heart Disease. <i>American Journal of Cardiology</i> , 2015, 115, 316-322.	0.7	23
75	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015, 169, 25-30.	1.2	61
76	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	1.0	144
77	Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. <i>Heart</i> , 2015, 101, 264-270.	1.2	0
78	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. <i>American Journal of Medicine</i> , 2015, 128, 297-302.	0.6	9
79	Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. <i>Circulation</i> , 2015, 132, .	1.6	0
80	Check It, Change It. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 828-834.	0.9	30
81	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	1.0	303
82	Differences in Short-Term Versus Long-Term Outcomes of Older Black Versus White Patients With Myocardial Infarction. <i>Circulation</i> , 2014, 130, 659-667.	1.6	30
83	Trends in Referral to Cardiac Rehabilitation After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2582-2583.	1.2	61
84	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	1.2	308
85	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 2005-2012.	1.6	73
86	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014, 383, 1059-1066.	6.3	186
87	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	0.8	11
88	Sources of Hospital-Level Variation in Major Bleeding Among Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 236-243.	0.9	7
89	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	1.2	84
90	Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction?. <i>American Heart Journal</i> , 2014, 167, 762-769.	1.2	16

#	ARTICLE	IF	CITATIONS
91	Response to Letter to the Editor by Lin et al. American Heart Journal, 2014, 167, e21.	1.2	0
92	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. Metabolism: Clinical and Experimental, 2014, 63, 554-561.	1.5	37
93	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood, 2014, 124, 3692-3698.	0.6	149
94	Association of Early Physician Follow-Up and 30-Day Readmission After Non-ST-Segment Elevation Myocardial Infarction Among Older Patients. Circulation, 2013, 128, 1206-1213.	1.6	43
95	The Value of Statistical Analysis Plans in Observational Research. JAMA - Journal of the American Medical Association, 2012, 308, 773.	3.8	89
96	Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. American Heart Journal, 2011, 162, 606-612.e1.	1.2	137
97	A Moment-Adjusted Imputation Method for Measurement Error Models. Biometrics, 2011, 67, 1461-1470.	0.8	19